Merus NV (Merus NV) EBIT per Share : $-3.04 (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Merus NV EBIT per Share?

Merus NV's EBIT per Share for the three months ended in Mar. 2024 was $-0.81. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.04.

During the past 3 years, the average EBIT per Share Growth Rate was -5.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was -9.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was -10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Merus NV's EBIT per Share or its related term are showing as below:

MRUS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -35.6 Med: -6.7 Max: -3
Current: -5.4

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Merus NV was -3.00% per year. The lowest was -35.60% per year. And the median was -6.70% per year.

MRUS's 3-Year EBIT Growth Rate is ranked worse than
60.69% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs MRUS: -5.40

Merus NV's EBIT for the three months ended in Mar. 2024 was $-46.81 Mil.

Merus NV EBIT per Share Historical Data

The historical data trend for Merus NV's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV EBIT per Share Chart

Merus NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-2.42

-2.59

-2.33

-3.56

-3.03

Merus NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.79	-0.70	-0.71	-0.82	-0.81

Merus NV EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Merus NV's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-156.547	/	51.605
=	-3.03

Merus NV's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-46.809	/	58.085
=	-0.81

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.04

Merus NV (NAS:MRUS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Merus NV EBIT per Share Related Terms

Thank you for viewing the detailed overview of Merus NV's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Merus NV (Merus NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

2GH:Germany

Address

Uppsalalaan 17, Utrecht, NLD, 3584 CT

Website

https://www.merus.nl

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Executives

Harry Shuman	officer: Chief Accounting Officer	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman	officer: EVP & General Counsel	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg	director, officer: President, CEO & PFO	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De	officer: Chief Technology Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy	director	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen	director
Anand Mehra	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor	director	C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki	director	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry	director	C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W	officer: SVP & Chief Scientific Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe	officer: SVP, CMO	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby	officer: EVP & Chief Scientific Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM